Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that it will present at the Jefferies Global Healthcare Conference taking place in New York City. Ivor Elrifi, Chief Executive Officer and Keeren Shah, Chief Operating and Financial Officer of Tiziana Life Sciences, will deliver a corporate presentation highlighting th
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that it will present at the Jefferies Global Healthcare Conference taking place in New York City. Ivor Elrifi, Chief Executive Officer and Keeren Shah, Chief Operating and Financial Officer of Tiziana Life Sciences, will deliver a corporate presentation highlighting the Company’s recent clinical and corporate updates.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.